Please login to the form below

Not currently logged in
Email:
Password:

Botox approved for upper limb spasticity

The US FDA has approved Allergan's Botox (onabotulinumtoxinA) for the treatment of elbow, wrist and finger stiffness in adults

Allergan has announced that the US FDA has approved Botox (onabotulinumtoxinA) for the treatment of increased elbow, wrist and finger muscle stiffness in adults with upper limb spasticity.

In treating upper limb spasticity, Botox is injected directly into the affected muscles. It works by blocking overactive nerve impulses that trigger muscle contractions.

Spasticity is a debilitating, although non-life-threatening, condition often experienced following a stroke. Spasticity of the upper limbs can also occur following spinal cord or traumatic brain injuries, or in patients affected by multiple sclerosis (MS) or cerebral palsy.

"The approval of Botox marks another important evolution in medical care, as we look to raise greater recognition and understanding of upper limb spasticity among patients affected by the condition, and refer them to a neurologist or physiatrist to explore their various treatment options," said Dr Mitchell F Brin, Allergan's senior vice president Global Development, chief scientific officer, Botox.

Data from clinical trials show that Botox had a persistent efficacy of around three months. It is the first and only neurotoxin approved by the FDA for the treatment of upper limb spasticity.

Although most commonly known for its cosmetic application to improve the appearance of frownlines, Botox was first approved by the FDA in 1989 as a treatment for certain eye muscle and eyelid spasm problems.

Botox is approved in around 80 countries for 21 different indications. It is approved in the US as a treatment for abnormal head position and neck pain caused by cervical dystonia and also as a therapy for severe underarm sweating in cases where topical applications are ineffective.

10th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics